Intrinsic Therapeutics Strengthens Sales Team with New Leaders
Intrinsic Therapeutics Appoints New Sales Leadership
Intrinsic Therapeutics, Inc., a pioneering medical technology company, is on a mission to transform the standard care for lumbar discectomy patients. Through its innovative Barricaid Annular Closure Device, the company has made strides in reducing reoperations due to reherniations by an impressive 81%. In line with this mission, the recent appointment of Mike Lytle and Dave Decker as Vice Presidents of Sales marks a significant advancement in their growth strategy.
Introducing Mike Lytle and Dave Decker
Mike Lytle and Dave Decker, both seasoned veterans in the spine and orthopedics market, collectively boast over 60 years of experience. Their deep understanding of the industry and established relationships with surgeons and distributors are assets that Intrinsic Therapeutics intends to leverage fully.
Professional Background of Dave Decker
Dave Decker, with his extensive background, brings over 30 years of experience in orthopedics and spine. His previous role as AVP for a leading spinal implant company saw his team achieve outstanding regional performance for three consecutive years. Decker’s previous tenure as Area Sales Director at NuVasive, where he was consistently recognized for his leadership, further establishes him as a key player in this sector. He stated, "Barricaid represents a major advancement in the treatment of disc herniation, enabling us to meet patient needs like never before." His vision for redefining standards of care aligns perfectly with Intrinsic's mission.
Mike Lytle’s Contributions to the Industry
On the other hand, Mike Lytle’s impressive 30-year background in medical devices includes significant roles in the spine industry. His previous successes at Orthofix/SeaSpine highlight his ability to lead productive teams, consistently achieving top performance. His personal journey, having experienced complications from a failed multilevel discectomy, fuels his passion for the work that Intrinsic is doing. Lytle emphasizes, "We have an obligation to ensure that every qualified patient has access to Barricaid so they can avoid the challenges I faced and live healthier lives." His commitment to improving patient outcomes is a driving force in his new role.
Barricaid: A Game Changer in Spine Surgery
The Barricaid device is a breakthrough in spinal surgery, aiming specifically to prevent reherniation and the need for reoperations in patients suffering from large annular defects post-lumbar discectomy. The device has already been implanted in over 12,000 patients, supported by a robust array of clinical studies involving diverse populations. Notably, a multicenter, Level I randomized controlled trial showcasing superior outcomes compared to discectomy alone was published in a respected medical journal with follow-up results extending five years.
Looking Forward: The Future of Intrinsic Therapeutics
With Mike Lytle and Dave Decker at the helm of sales, Intrinsic Therapeutics is well-positioned to enhance patient care for discectomy procedures. Their leadership not only enriches the company culture but also accelerates its goals of increasing patient access to innovative care solutions. Under their guidance, Intrinsic aims to reach more patients and involve more surgeons in utilizing Barricaid for improved health outcomes.
Frequently Asked Questions
What are the roles of Mike Lytle and Dave Decker at Intrinsic Therapeutics?
Mike Lytle and Dave Decker have been appointed as Vice Presidents of Sales, overseeing sales efforts and expanding market reach.
What is Barricaid?
Barricaid is a novel device designed to prevent reherniation in patients who undergo lumbar discectomy surgery.
How has Barricaid impacted patient care?
Barricaid has successfully reduced the need for reoperations due to disc herniations, significantly enhancing patient outcomes.
How many patients have received Barricaid?
Over 12,000 patients have been treated with Barricaid since its introduction in the market.
What is Intrinsic Therapeutics’ mission?
Intrinsic Therapeutics aims to redefine the standard of care for patients undergoing lumbar discectomy procedures, improving their post-operative lives.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
